Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

Empagliflozin (JARDIANCE^®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

What is the clinical implication of Empagliflozin (JARDIANCE) in the full spectrum of HF?

Document ID: PC-PH-104059

06/10/2022

Author: Boehringer Ingelheim

Related content